glp 1 and kidney GLP-1 receptor agonists next-generation metabolic hormone therapies in chronic disease Mechanisms of GLP-1 receptor–independent renoprotective
Description
On the contrary, the following GLP-1 RAs were not associated with a significant increased risk of diarrhea: exenatide (RR 0.1756 [95% CI 0.0231, 1.3355
Conclusion GLP-1 receptor agonists have fundamentally reshaped obesity treatment by enabling unprecedented pharmacological weight loss
Animal data provides some support for the concept
N Engl J Med 2010;362:590-9.ArticlePubMedPMC 342
About 12% of American adults are currently taking a GLP-1 medication for weight loss or type 2 diabetes treatment
